| Popis: |
Peng Guo,1 Rui Li,2 Tie Hua Piao,3 Chun Lan Wang,3 Xiao Lu Wu,3 Hong Yan Cai3 1College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Changchun, 130000, People’s Republic of China; 2Graduate School, Beijing University of Chinese Medicine, Beijing, 100000, People’s Republic of China; 3Pulmonology Department, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People’s Republic of ChinaCorrespondence: Hong Yan Cai, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People’s Republic of China, Email 774009408@qq.comAbstract: Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema, and small airway obstruction. Incompletely reversible airflow limitation, inflammation, excessive mucus secretion and bronchial mucosal epithelial lesions are the main pathological basis of the disease. The prevalence of COPD is increasingly worldwide, which has caused the burden on individuals and society. This paper summarizes the pathogenesis of COPD and clarifies the effect and mechanism of the latest targeted drugs for COPD. Besides, we focus on NOD-like receptor thermal protein domain associated protein 3 inflammasome (NLRP3 inflammasome). NLRP3 can promote production of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3 is an important factor in the migratory aggregation of macrophages and neutrophils and the generation of oxidative stress. Inhibition of NLRP3 inflammasome indirectly blocks the inflammatory effects of IL-1β and IL-18, which may be regarded as an ideal target for COPD treatment.Keywords: chronic obstructive pulmonary disease, pathogenesis, targeted drugs, NLRP3 |
